Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL)

Description

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing of "brimonidine or its salts" on the Prescription Drug List (PDL). Note that both the human and veterinary parts of the PDL were revised with the addition of a qualifier.

Resources

Name Format Description Link
21 https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-revision-brimonidine.html
21 https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/modification-revision-brimonidine.html

Tags

Topics

Categories